Standardized 4-year financial series for Axsome Therapeutics, Inc., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.
Quarterly coverage: 13 periods · latest quarter FY2025-Q3 · TTM revenue growth 105.2%.
The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.
| Fiscal year | Revenue | Adj. EBITDA | EBIT | Net result | Op. cash flow | Capex | Net debt | Status |
|---|---|---|---|---|---|---|---|---|
| FY2022 | 50M | — | -180M | -187M | -117M | -702K | -107M | missing adjusted ebitda · missing gross profit |
| FY2023 | 271M | — | -232M | -239M | -145M | -582K | -208M | missing adjusted ebitda · missing cost of revenue · missing gross profit |
| FY2024 | 386M | — | -281M | -287M | -128M | -270K | -135M | missing adjusted ebitda · missing cost of revenue · missing gross profit |
| FY2025 | 638M | — | -167M | -183M | -93M | -480K | -135M | missing adjusted ebitda · missing cost of revenue · missing gross profit |
SEC EDGAR companyfacts · XBRL · consolidated_reported
missing_adjusted_ebitda · missing_gross_profit
Open official source filingSEC EDGAR companyfacts · XBRL · consolidated_reported
missing_adjusted_ebitda · missing_cost_of_revenue · missing_gross_profit
Open official source filingSEC EDGAR companyfacts · XBRL · consolidated_reported
missing_adjusted_ebitda · missing_cost_of_revenue · missing_gross_profit
Open official source filingSEC EDGAR companyfacts · XBRL · consolidated_reported
missing_adjusted_ebitda · missing_cost_of_revenue · missing_gross_profit
Open official source filing